Feasibility of somatostatin receptor-targeted imaging for detection of myocardial inflammation: A pilot study
Gallium-68 Dotatate binds preferentially to somatostatin receptor (sstr) subtype-2 (sstr-2) on inflammatory cells. We aimed at investigating the potential clinical use of sstr-targeted imaging for the detection of myocardial inflammation.
Thirteen patients, with suspected cardiac sarcoidosis (CS) based on clinical history and myocardial uptake on recent fluorine-18 fluorodeoxyglucose (FDG) PET, were enrolled to undergo Dotatate PET after FDG-PET (median time 37 days [IQR 25-55]). Additionally, we investigated ex-vivo the immunohistochemistry expression of sstr-2 in 3 explanted sarcoid hearts.
All FDG scans showed cardiac uptake (focal/multifocal = 6, focal on diffuse/heterogeneous = 7), and 46% (n = 6) extra-cardiac uptake (mediastinal/hilar). In comparison, Dotatate scans showed definite abnormal cardiac uptake (focal/multifocal) in 4 patients, probably abnormal (heterogenous/patchy) in 3, and negative uptake in 6 cases. Similarly, 6 patients had increased mediastinal/hilar Dotatate uptake. Overall concordance of FDG and Dotatate uptake was 54% in the heart and 100% for thoracic nodal activity. Quantitatively, FDG maximum standardized uptake value was 5.0 times [3.8-7.1] higher in the heart, but only 2.25 times [1.7-3.0; P = .019] higher in thoracic nodes relative to Dotatate. Ex-vivo, sstr-2 immunostaining was weakly seen within well-formed granulomas in all 3 examined sarcoid heart specimens with no significant staining of background myocardium or normal myocardium.
Our preliminary data suggest that, compared to FDG imaging, somatostatin receptor-targeted imaging may be less sensitive for the detection of myocardial inflammation, but comparable for detecting extra-cardiac inflammation.
KeywordsSarcoidosis somatostatin receptor myocardial inflammation PET
Positron emission tomography
Somatostatin receptor (sstr) subtype-2
This work was supported by a grant from the Radiological Society of North America Research & Education Foundation Board of Trustees (RF1632), Institutional Funds, and a Training Grant from the National Institutes of Health (1T32HL094301).
The authors have no conflicts of interest to disclose.
- 5.Hiramitsu S, Morimoto S, Uemura A, Kato Y, Kimura K, Ohtsuki M, et al. National survey on status of steroid therapy for cardiac sarcoidosis in japan. Sarcoidosis Vasc Diffus Lung Dis 2005;22:210–3.Google Scholar
- 6.Osborne MT, Hulten EA, Murthy VL, Skali H, Taqueti VR, Dorbala S, et al. Patient preparation for cardiac fluorine-18 fluorodeoxyglucose positron emission tomography imaging of inflammation. J Nucl Cardiol 2016.Google Scholar
- 9.Folco EJ, Sheikine Y, Rocha VZ, Christen T, Shvartz E, Sukhova GK, et al. Hypoxia but not inflammation augments glucose uptake in human macrophages: Implications for imaging atherosclerosis with 18fluorine-labeled 2-deoxy-d-glucose positron emission tomography. J Am Coll Cardiol 2011;58:603–14.CrossRefGoogle Scholar
- 10.Sibille L, Chambert B, Collombier L, Kotzki PO, Boudousq V. False positive 18f-fdg pet/ct in cardiac sarcoidosis. J Mol Biol Mol Imaging 2015;2:1020.Google Scholar
- 14.Smedema JP, van Kroonenburgh MJ, Snoep G, Backes W, Gorgels AP. Images in cardiovascular medicine. Cardiac sarcoidosis in a patient with hypertrophic cardiomyopathy demonstrated by magnetic resonance imaging and single photon emission computed tomography dual-isotope scintigraphy. Circulation 2004;110:e529–31.CrossRefGoogle Scholar
- 17.Balon HR, Goldsmith SJ, Siegel BA, Silberstein EB, Krenning EP, Lang O, et al. Procedure guideline for somatostatin receptor scintigraphy with (111)in-pentetreotide. J Nucl Med 2001;42:1134–8.Google Scholar
- 22.Okumura W, Iwasaki T, Toyama T, Iso T, Arai M, Oriuchi N, et al. Usefulness of fasting 18f-fdg pet in identification of cardiac sarcoidosis. J Nucl Med 2004;45:1989–98.Google Scholar
- 28.Lapa C, Reiter T, Kircher M, Schirbel A, Werner RA, Pelzer T, et al. Somatostatin receptor based pet/ct in patients with the suspicion of cardiac sarcoidosis: An initial comparison to cardiac mri. Oncotarget 2016;7:77807–14.Google Scholar